Literature DB >> 30649462

What Should We Do Better? Lessons from Negative Results of a Biomarker Validation Study.

Francesca Battaglin1, Heinz-Josef Lenz1.   

Abstract

Mesh：

Substances：

Year:  2019        PMID： 30649462      PMCID： PMC6695307          DOI： 10.1093/jnci/djy217

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  24 in total

1.  Consensus molecular subtypes of colorectal cancer are recapitulated in in vitro and in vivo models.

Authors:  Janneke F Linnekamp; Sander R van Hooff; Pramudita R Prasetyanti; Raju Kandimalla; Joyce Y Buikhuisen; Evelyn Fessler; Prashanthi Ramesh; Kelly A S T Lee; Grehor G W Bochove; Johan H de Jong; Kate Cameron; Ronald van Leersum; Hans M Rodermond; Marek Franitza; Peter Nürnberg; Laura R Mangiapane; Xin Wang; Hans Clevers; Louis Vermeulen; Giorgio Stassi; Jan Paul Medema
Journal:  Cell Death Differ       Date:  2018-01-05       Impact factor: 15.828

Review 2.  Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology.

Authors:  Antonia R Sepulveda; Stanley R Hamilton; Carmen J Allegra; Wayne Grody; Allison M Cushman-Vokoun; William K Funkhouser; Scott E Kopetz; Christopher Lieu; Noralane M Lindor; Bruce D Minsky; Federico A Monzon; Daniel J Sargent; Veena M Singh; Joseph Willis; Jennifer Clark; Carol Colasacco; R Bryan Rumble; Robyn Temple-Smolkin; Christina B Ventura; Jan A Nowak
Journal:  J Mol Diagn       Date:  2017-02-06       Impact factor: 5.568

3.  Immunogenic death of colon cancer cells treated with oxaliplatin.

Authors:  A Tesniere; F Schlemmer; V Boige; O Kepp; I Martins; F Ghiringhelli; L Aymeric; M Michaud; L Apetoh; L Barault; J Mendiboure; J-P Pignon; V Jooste; P van Endert; M Ducreux; L Zitvogel; F Piard; G Kroemer
Journal:  Oncogene       Date:  2009-11-02       Impact factor: 9.867

4.  Gender-specific genomic profiling in metastatic colorectal cancer patients treated with 5-fluorouracil and oxaliplatin.

Authors:  Michael A Gordon; Wu Zhang; Dongyun Yang; Syma Iqbal; Anthony El-Khouiery; Fumio Nagashima; Georg Lurje; Melissa Labonte; Peter Wilson; Andy Sherrod; Robert D Ladner; Heinz-Josef Lenz
Journal:  Pharmacogenomics       Date:  2011-01       Impact factor: 2.533

5.  Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors.

Authors:  François Ghiringhelli; Lionel Apetoh; Antoine Tesniere; Laetitia Aymeric; Yuting Ma; Carla Ortiz; Karim Vermaelen; Theocharis Panaretakis; Grégoire Mignot; Evelyn Ullrich; Jean-Luc Perfettini; Frédéric Schlemmer; Ezgi Tasdemir; Martin Uhl; Pierre Génin; Ahmet Civas; Bernhard Ryffel; Jean Kanellopoulos; Jürg Tschopp; Fabrice André; Rosette Lidereau; Nicole M McLaughlin; Nicole M Haynes; Mark J Smyth; Guido Kroemer; Laurence Zitvogel
Journal:  Nat Med       Date:  2009-09-20       Impact factor: 53.440

6.  Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.

Authors:  Lionel Apetoh; François Ghiringhelli; Antoine Tesniere; Michel Obeid; Carla Ortiz; Alfredo Criollo; Grégoire Mignot; M Chiara Maiuri; Evelyn Ullrich; Patrick Saulnier; Huan Yang; Sebastian Amigorena; Bernard Ryffel; Franck J Barrat; Paul Saftig; Francis Levi; Rosette Lidereau; Catherine Nogues; Jean-Paul Mira; Agnès Chompret; Virginie Joulin; Françoise Clavel-Chapelon; Jean Bourhis; Fabrice André; Suzette Delaloge; Thomas Tursz; Guido Kroemer; Laurence Zitvogel
Journal:  Nat Med       Date:  2007-08-19       Impact factor: 53.440

7.  Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.

Authors:  Thierry André; Armand de Gramont; Dewi Vernerey; Benoist Chibaudel; Franck Bonnetain; Annemilaï Tijeras-Raballand; Aurelie Scriva; Tamas Hickish; Josep Tabernero; Jean Luc Van Laethem; Maria Banzi; Eduard Maartense; Einat Shmueli; Goran U Carlsson; Werner Scheithauer; Demetris Papamichael; Marcus Möehler; Stefania Landolfi; Pieter Demetter; Soudhir Colote; Christophe Tournigand; Christophe Louvet; Alex Duval; Jean-François Fléjou; Aimery de Gramont
Journal:  J Clin Oncol       Date:  2015-11-02       Impact factor: 44.544

8.  Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.

Authors:  Richard A Adams; Angela M Meade; Matthew T Seymour; Richard H Wilson; Ayman Madi; David Fisher; Sarah L Kenny; Edward Kay; Elizabeth Hodgkinson; Malcolm Pope; Penny Rogers; Harpreet Wasan; Stephen Falk; Simon Gollins; Tamas Hickish; Eric M Bessell; David Propper; M John Kennedy; Richard Kaplan; Timothy S Maughan
Journal:  Lancet Oncol       Date:  2011-06-05       Impact factor: 41.316

9.  MAVERICC, a Randomized, Biomarker-stratified, Phase II Study of mFOLFOX6-Bevacizumab versus FOLFIRI-Bevacizumab as First-line Chemotherapy in Metastatic Colorectal Cancer.

Authors:  Aparna R Parikh; Fa-Chyi Lee; Linda Yau; Han Koh; James Knost; Edith P Mitchell; Ivan Bosanac; Nicholas Choong; Frank Scappaticci; Christoph Mancao; Heinz-Josef Lenz
Journal:  Clin Cancer Res       Date:  2018-09-17       Impact factor: 13.801

10.  3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial.

Authors:  Timothy J Iveson; Rachel S Kerr; Mark P Saunders; Jim Cassidy; Niels Henrik Hollander; Josep Tabernero; Andrew Haydon; Bengt Glimelius; Andrea Harkin; Karen Allan; John McQueen; Claire Scudder; Kathleen Anne Boyd; Andrew Briggs; Ashita Waterston; Louise Medley; Charles Wilson; Richard Ellis; Sharadah Essapen; Amandeep S Dhadda; Mark Harrison; Stephen Falk; Sherif Raouf; Charlotte Rees; Rene K Olesen; David Propper; John Bridgewater; Ashraf Azzabi; David Farrugia; Andrew Webb; David Cunningham; Tamas Hickish; Andrew Weaver; Simon Gollins; Harpreet S Wasan; James Paul
Journal:  Lancet Oncol       Date:  2018-04       Impact factor: 41.316
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.